NEW YORK ( TheStreet) -- PetMed Express (Nasdaq: PETS) is trading at unusually high volume Monday with 1.2 million shares changing hands. It is currently at five times its average daily volume and trading down $2.67 (-19.4%) at $11.09 as of 11 a.m. ET. PetMed Express has a market cap of $265.4 million and is part of the health care sector and drugs industry. Shares are up 32.6% year to date as of the close of trading on Friday. PetMed Express, Inc., doing business as 1-800-PetMeds, operates a pet pharmacy in the United States. It markets non-prescription and prescription pet medications; and other health products for dogs and cats, as well as direct to consumers. The company has a P/E ratio of 16.3, below the average drugs industry P/E ratio of 16.7 and below the S&P 500 P/E ratio of 17.7. TheStreet Ratings rates PetMed Express as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and reasonable valuation levels. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, weak operating cash flow and feeble growth in the company's earnings per share. You can view the full PetMed Express Ratings Report. See all heavy volume stocks in our stocks moving on unusual volume list or get investment ideas from our investment research center.
More from Markets
Trump Says U.S. and China Reach Preliminary Trade Accord
The president cited progress in the 18-month trade war on topics including currency, intellectual property and financial services. And China will buy more U.S. agricultural products. The U.S. for its part will delay the tariff increase that was due next week.
Stocks End Higher; Trump Announces 'Substantial Phase One' Trade Deal
Stocks finish sharply higher Friday on signs the U.S. and China have taken steps to ease trade tensions between the two countries.
Amazon Earnings May Not Impress, But Here's Why the Stock Could Still Be a Buy
Amazon Web Services remains a huge bright spot for the stock, analysts say.